Related references
Note: Only part of the references are listed.Analytical validation of GMEX rapid point-of-care CYP2C19 genotyping system for the CHANCE-2 trial
Xia Meng et al.
STROKE AND VASCULAR NEUROLOGY (2021)
Antiplatelet Treatment to Prevent Early Recurrent Stroke
Peter M. Rothwell
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Efficacy of Clopidogrel for Prevention of Stroke Based on CYP2C19 Allele Status in the POINT Trial
James F. Meschia et al.
STROKE (2020)
Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial
Yilong Wang et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke
P. Amarenco et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA
S. Claiborne Johnston et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack A Systematic Review and Meta-Analysis
Yuesong Pan et al.
CIRCULATION (2017)
Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)
Yongjun Wang et al.
STROKE (2017)
Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke
Rui Liu et al.
ACTA PHARMACOLOGICA SINICA (2016)
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack
Yilong Wang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke
Pierre Amarenco et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response
Yan Han et al.
CNS NEUROSCIENCE & THERAPEUTICS (2015)
CYP2C19 Metabolizer Status and Clopidogrel Efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study
Caitrin W. McDonough et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2015)
Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack
Yongjun Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Prasugrel Overcomes High On-Clopidogrel Platelet Reactivity Post-Stenting More Effectively Than High-Dose (150-mg) Clopidogrel The Importance of CYP2C19*2 Genotyping
Dimitrios Alexopoulos et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2011)
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
Alan R. Shuldiner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Inhibition of platelet aggregation by AZD6140, A reversible oral P2Y12 receptor antagonist, compared with clopidogral in patients with acute coronary syndrome
Robert F. Storey et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Share Paper
